EXACT Sciences Corporation

EXACT Sciences — Conference Presentation (January 2020)

32 slides from EXACT Sciences's conference presentation, Jan 13, 2020

  1. Slide 1: Building the Leading Cancer Diagnostics Company

    Exhibit 99.2 Building the Leading Cancer Diagnostics Company Kevin Conroy, Chairman and CEO January 15, 2020 Exact Sciences

  2. Slide 2: Safe harbor statement

    Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections.

  3. Slide 3: We strive to change lives through earlier detection and smarter answers

    We strive to change lives through earlier detection and smarter answers for cancer patients. Exact Sciences 3

  4. Slide 4: 2019 Screening results

    2019 Screening results Preliminary, unaudited financials Q4 2019 2019 Revenue $229-230M $809.5-810.5M Cologuard® tests 477K 1.68M 78% 2019 Y/Y revenue New Cologuard growth providers 12K 50K Exact Sciences 4

  5. Slide 5: 2019 Precision Oncology results

    2019 Precision Oncology results Preliminary, unaudited financials Partial Proforma Proforma Q4 2019* Q4 2019** 2019** Revenue $65-66M $118-119M $455-456M 16% Oncotype DX® 2019 Y/Y revenue tests 23K 41K 156K growth *Revenue reported on a GAAP basis from the close of the Genomic Health combination thr

  6. Slide 6: Key 2019 accomplishments

    Key 2019 accomplishments Genomic Health combination Cologuard tests increased 80% Power the Partnership Cologuard ordering providers increased 34% Lab capacity expanded to 7M tests Cologuard 45-49 label expansion Enhance Cologuard Cologuard 2.0 data release BLUE-C initiation Advance Liquid Biopsy Li

  7. Slide 7: Leading, global, advanced cancer diagnostics company

    Leading, global, advanced cancer diagnostics company 4,000+ employees 1,000+ commercial organization $1.6B+ projected 2020 revenue Headquarters Offices Exact Sciences 7

  8. Slide 8: Positioned for long-term success

    Positioned for long-term success PRECISION SCREENING ONCOLOGY INTERNATIONAL PIPELINE Field teams Field teams Field team/presence R&D team 500 primary care 100 oncology 40 oncology 250 people Liver 60 gastroenterology urology countries 50 90 Pancreatic health system Esophageal 35 Bladder Exact Scienc

  9. Slide 9: 2020 Corporate Priorities

    2020 Corporate Priorities Deliver More Answers Enhance Customer Experience Power New Growth Exact Sciences 9

  10. Slide 10: Screening

    Screening Exact Sciences 10

  11. Slide 11: Colorectal cancer: America's second deadliest cancer

    Colorectal cancer: America’s second deadliest cancer Lung 53,200 Colorectal Pancreatic annual deaths Breast Prostate Liver Source: American Cancer Society, Cancer Facts & Figures 2020; all figures annual Exact Sciences 11

  12. Slide 12: Detecting colorectal cancer earlier is critical

    Detecting colorectal cancer earlier is critical Diagnosed in Stages I or II Diagnosed in Stage IV 9/10 survive 5 years 1/10 survive 5 years Source: SEER 18 2009-2015, colorectal cancer statistics Exact Sciences 12

  13. Slide 13: Cologuard: addressing the colorectal cancer challenge

    Cologuard: addressing the colorectal cancer challenge 94% Early-stage cancer sensitivity* Easy to use No preparation No time off work Non-invasive No sedation 24/7 customer support For adults 45 years or older and at average risk Developed with *For stage I and II cancers; 92% sensitivity overall, 8

  14. Slide 14: Demand fueling strong Cologuard growth

    Demand fueling strong Cologuard growth $229-230M* 3.5M+ people screened since launch $35M 4Q16 4Q19 *Preliminary, unaudited Screening business unit Q4 2019 revenue Exact Sciences 14

  15. Slide 15: Capturing a large U.S. screening opportunity

    Capturing a large U.S. screening opportunity 5.4% adoption 106M 40% Americans goal $18B total addressable U.S. colorectal cancer market screening population Source: Exact Sciences estimates, assuming 106 million average-risk, asymptomatic people ages 45-85, revenue per test of $500-$525, and 3-year

  16. Slide 16: Cologuard growth opportunities

    Cologuard growth opportunities Near-term Sales team productivity Mid-term 19M people ages 45-49 Long-term Cologuard 2.0 enhancements Exact Sciences 16

  17. Slide 17: Precision Oncology

    Precision Oncology Exact Sciences 17

  18. Slide 18: Breast cancer: America's fourth deadliest cancer

    Breast cancer: America’s fourth deadliest cancer Lung 42,690 Colorectal Pancreatic annual deaths Breast Prostate Liver Source: American Cancer Society, Cancer Facts & Figures 2020; all figures annual Exact Sciences 18

  19. Slide 19: Guiding therapy for early-stage breast cancer

    Guiding therapy for early-stage breast cancer Prognostic and predictive Early stage: HER2 (-) ER (+) Node (-) Node (+) 1-2 Substantial No Chemotherapy Benefit 2 Chemotherapy Benefit (0-25) (26-100) Recurrence Score® 0 (RS) Result 26 100 1. Sparano et al. N Engl J Med. 2018 2. Geyer et al. NPJ Breast

  20. Slide 20: Oncotype DX: standard of care in breast cancer

    Oncotype DX: standard of care in breast cancer 1M+ 96K+ 150+ patients tested patients worldwide with published publications prospective outcomes ASCO® NCCN® ESMO ST. GALLEN NICE Exact Sciences 20

  21. Slide 21: Real-world evidence supporting Oncotype DX adoption

    Real-world evidence supporting Oncotype DX adoption TAILORx RxPONDER 10,000 women, 9 years 4,000 women, up to 10 years Early-stage, node-negative Early-stage, node-positive breast cancer breast cancer Published in June 2018 Expected readout in 2022 Exact Sciences 21

  22. Slide 22: Capturing a large global breast cancer opportunity

    Capturing a large global breast cancer opportunity U.S. opportunity International opportunity* 68% adoption 14% adoption 140K $500M 200K $400M people opportunity people opportunity Source: Exact Sciences estimates *Opportunity in key strategic markets Exact Sciences 22

  23. Slide 23: Helping inform prostate cancer treatment recommendations

    Helping inform prostate cancer treatment recommendations Predicts clinical risk and tumor aggressiveness surveillance treatment For low- and 33K annual Helps inform Changes 15% adoption intermediate- prostate cancer active surveillance treatment in $440M U.S. risk patients deaths in U.S.1 vs. aggres

  24. Slide 24: Pipeline

    Pipeline Exact Sciences 24

  25. Slide 25: Clinical pipeline across cancer types

    CUINIC EXACT S PANCREATIC ESOPHAGEAL BLADDER OVARIAN S COLORECTAL PROSTATE BREAST 25 Exact Sciences

  26. Slide 26: Deep R&D capabilities

    Deep R&D capabilities Multiple classes of biomarkers Proprietary DNA chemistry State-of-the-art labs Flexible, automated platform Exact Sciences 26 26

  27. Slide 27: Liver cancer: America's sixth deadliest cancer

    Liver cancer: America’s sixth deadliest cancer Lung 30,160 Colorectal Pancreatic annual deaths Breast Prostate Liver Source: American Cancer Society, Cancer Facts & Figures 2020; all figures annual Exact Sciences 27

  28. Slide 28: Regular liver cancer testing leads to better outcomes

    Regular liver cancer testing leads to better outcomes Under regular testing Not under regular testing 6/10 survive 3 years 3/10 survive 3 years Source: Kuo, YH et al., Eur J Cancer (2010) Exact Sciences 28

  29. Slide 29: Next steps to capturing a large U.S. liver cancer opportunity

    Next steps to capturing a large U.S. liver cancer opportunity 3M Additional data in Americans 2020 $1.5B Test available in total U.S. 2H20 addressable market Note: Expect additional data in 2020 and to make the liver cancer test available in 2H20 Source: Exact Sciences estimates; total addressable m

  30. Slide 30: Earlier detection and smarter answers across several cancer types

    Earlier detection and smarter answers across several cancer types Lung Colorectal Pancreatic Breast Prostate Liver Note: expect to make liver cancer test available in 2020 Source: American Cancer Society, Cancer Facts & Figures 2020; all figures annual Exact Sciences 30

  31. Slide 31: The leading global cancer diagnostics company

    The leading global cancer diagnostics company $1.6B+ projected 2020 revenue 4.7M+ people tested to-date $1.2B+ and growing projected 2020 gross profit Note: 4.7M+ total people tested with Cologuard and Oncotype DX products combined Exact Sciences 31

  32. Slide 32: Exact Sciences

    EXACT SCIENCES Exact Sciences

Exact Sciences — Conference Presentation (January 2020) on 6ix